Novel targeted therapies and combinations for the treatment of multiple Myeloma

Amit Agarwal, Daruka Mahadevan

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Multiple myeloma is a B-cell neoplasm that is characterized by clonal proliferation of terminally differentiated plasma cells. Approximately 20,000 new cases are diagnosed each year with a prevalence of about 60,000. Characteristic clinical features include bone disease, hypercalcemia, renal disease, anemia and infections. Advancements in our understanding of multiple myeloma have led to a significant impact in the natural history of the disease. Despite these advances the disease remains incurable and most patients invariably relapse and die. Our understanding of the transformation of normal plasma cells into myeloma cells and the interaction between myeloma cells and elements of the bone marrow microenvironment that sustain proliferation and survival has significantly improved. This knowledge has paved the way for the development of novel drugs that target the genetic and molecular changes that underlie myeloma pathophysiology. In this review we discuss several of these novel agents. We focus on the specific pathways targeted by these drugs and the role they may play in development or progression of multiple myeloma. We also discuss the proposed mechanism of action of these drugs and correlate these to clinical trials where they have been investigated.

Original languageEnglish (US)
Pages (from-to)2-15
Number of pages14
JournalCardiovascular and Hematological Disorders - Drug Targets
Volume13
Issue number1
DOIs
StatePublished - Apr 30 2013
Externally publishedYes

Keywords

  • HDAC inhibitors
  • IMiDs
  • Monoclonal antibodies
  • mTOR inhibitors
  • Multiple myeloma
  • Proteasome inhibitors
  • Targeted therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Hematology
  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Novel targeted therapies and combinations for the treatment of multiple Myeloma'. Together they form a unique fingerprint.

Cite this